北京健康(02389.HK)預期年度虧損增加
格隆匯3月14日丨北京健康(02389.HK)公吿,公司預期截至2024年12月31日止年度的公司擁有人應占虧損較2023年同期增加約55,000,000港元。
本年度,集團的日常經營業務維持相對穩定,虧損增加主要原因是受以下費用淨增加所影響:(1)由於加元及人民幣貶值,導致本年度錄得匯兑虧損約29,290,000港元,而去年同期則錄得匯兑收益約9,237,000港元;(2)集團持有的上市聯營公司的股價於本年度下跌,集團進行減值評估時,作出減值撥備約11,539,000港元,而去年同期則作出約1,211,000港元減值回撥;(3)本年度確認分佔合營公司的虧損增加7,718,000港元,主要是因利率上升導致合營公司的利息支出增加;及(4)去年度就一項其他應收款作出約14,165,000港元減值,而本年度相類同的資產減值則約5,000,000港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.